Despite growing complaints about the negative reputation of the pharmaceutical industry, little fundamental research data has been available on the topic so far.

A detailed analysis by George P.  Sillup and Stephen J. Porth published in the International Journal of Pharmaceutical and Healthcare Marketing supports the evidence. Following an audit of the top five U.S. newspapers over two years (2004-2005), Sillup and Porth concluded that the overall coverage of the pharmaceutical industry was primarily negative (69.5% and 60.1% in 2004 and 2005, respectively) and that “pharmaceutical companies need to take action to address the negative impression about them.”  » Read more...

• March 8th-10th, 2010: BIO-Europe Spring, Barcelona, Spain. Further information at www.ebdgroup.com/bes
• April 21st-22nd, 2010: Deutsche Biotechnologietage, Berlin, Germany. Further information at http://www.biotechnologietage-2010.de/ (German language only)
• May 19th-20th, 2010: Bio€quity Europe, Zurich, Switzerland. Further information at www.ebdgroup.com/bee

Please feel free to contact akampion for IR/PR support – we will be happy to set up media and investor meetings for your company and help you update your corporate presentation and hand-outs: info (at) akampion.com

Reducing carbon dioxide emission is an enormous task, removing it from the atmosphere at low cost anywhere in the world maybe much more efficient and easier to accomplish (and faster!).

Imagine a bottle brush where all the bristles are artificial leaves – that‘s exactly the device Klaus S. Lackner, Director of the Lenfest Center for Sustainable Energy at Columbia University http://redir.ec/earth has developed.  » Read more...

SuppreMol GmbH, a privately held biopharmaceutical company developing novel therapeutics for the treatment of autoimmune diseases, today announced that Dr. Robert Phelps has joined the Company as Head of Business Development & Licensing.

See the full release at SupperMol´s website.

Analysis of biopsy sampling procedures a prerequisite for the development of future individualized cancer therapies

Hamburg-based Indivumed GmbH has been awarded a subcontract by SAIC-Frederick, Inc., under its prime contract with the U.S. National Cancer Institute (NCI) to assess the impact of sampling procedures on the integrity of cancer biospecimens and key data derived from them.  » Read more...